Generic-Reglan Suits Doomed By Catch-22, 6th Circ. Says

Law360, Los Angeles (December 2, 2013, 6:13 PM EST) -- A Sixth Circuit panel on Monday refused to revive seven lawsuits alleging a generic version of digestion medication Reglan caused users to develop a serious neurological condition, ruling the plaintiffs were caught in a catch-22 preventing them from bringing claims against generic or brand-name manufacturers.

Writing for the panel U.S. Circuit Judge Ronald Lee Gilman, upheld a lower court's decision dismissing the cases on the grounds that the plaintiffs had taken metoclopramide, the generic name for Reglan, and brand-name manufacturers couldn’t be held liable under the...
To view the full article, register now.




Case Information

Case Title

Gloria Strayhorn, et al v. Wyeth Pharmaceuticals, Inc., et al

Case Number



Appellate - 6th Circuit

Nature of Suit

4365 P.I.: Product Liability

Date Filed

October 4, 2012

Law Firms


Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.